Skip to main content

Table 1 Subclinical rejection cohort patient characteristics, used for activity-based protein profiling

From: Activity-based protein profiling guided identification of urine proteinase 3 activity in subclinical rejection after renal transplantation

Patient characteristic

All n = 18

Normal transplant n = 6

Subclinical TCMR Banff ≥ 1A n = 6

Clinical TCMR Banff ≥ 1A n = 6

At transplant

 Recipient age (years)

50.6 ± 9.8

48.7 ± 5.1

52.2 ± 4.4

50.9 ± 16.5

 Recipient sex (male)

15 (83.3)

6 (33.3)

4 (22.2)

5 (27.8)

 Recipient race (Caucasian)

17 (94.4)

5 (27.8)

6 (33.3)

6 (33.3)

Cause of end-stage renal disease

 Diabetes

4 (22.2)

3 (50.0)

0

1 (16.7)

 Glomerulonephritis

7 (38.9)

2 (33.3)

3 (50.0)

2 (33.3)

 Polycystic kidney disease or congenital

5 (27.8)

1 (16.7)

2 (33.3)

2 (33.3)

 Hypertension

1 (0.06)

0

0

1 (16.7)

 Drug toxicity (lithium)

1 (0.06)

0

1 (16.7)

0

HLA mismatch

3.78 ± 1.4

3.17 (1.8)

4.17 (1.5)

4.0 (0.9)

Panel reactive antibody (PRA)

0.78 ± 2.3

2.33 ± 3.7

0

0

Donor type (living)

12 (66.7)

3 (16.7)

3 (16.7)

6 (33.3)

Donor age (years)

39.6 ± 13.2

38.8 ± 14.8

38.3 ± 17.7

41.5 ± 7.2

Induction therapy (none/basiliximab/thymoglobulin)

13/4/1

5/0/1

4/2/0

4/2/0

Post-transplant

 Maintenance therapy: tacrolimus, mycophenolate mofetil and prednisone

14 (77.8)

6 (33.3)

4 (22.2)

4 (22.2)

 Delayed graft function (dialysis in the 1st week post-transplant)

0

0

0

0

 Biopsy time (weeks post-transplant)

15.7 ± 10.0

20.8 ± 12.0

14.3 ± 9.0

11.8 ± 7.8

 Banff i score

1.6 ± 1.0

0.3 ± 0.8

2.2 ± 0.4

2.2 ± 0.4

 Banff t score

1.7 ± 1.3

0.5 ± 1.2

2.7 ± 0.5

1.8 ± 1.0

 Banff v score

0.2 ± 0.7

0

0

0.7 ± 1.2

 Banff g score

0.2 ± 0.7

0

0

0.5 ± 1.2

 Banff ci score

0.4 ± 0.8

0.3 ± 0.5

0.5 ± 0.5

0.5 ± 1.2

 Banff ct score

0.6 ± 0.6

0.7 ± 0.5

0.5 ± 0.5

0.7 ± 0.8

 Banff cv score

0.5 ± 0.9

0.4 ± 0.9

0.3 ± 0.5

0.75 ± 1.5

 Banff cg score

0.1 ± 0.3

0.2 ± 0.4

0

0.2 ± 0.4

 Serum creatinine at biopsy (µmol/L)

137.2 ± 45.4

125.4 ± 25.6

113.0 ± 44.1

173.2 ± 44.2

 MDRD eGFR at biopsy (mL/min)

54.5 ± 18.8

59.4 ± 15.7

64.0 ± 19.1

40.1 ± 14.3

 Total urine protein (g/day)

0.19 ± 0.2

0.15 ± 0.1

0.14 ± 0.07

0.28 ± 0.3

  1. Data are reported as mean ± SD, or total count (total %)
  2. Other maintenance immunosuppression was triple therapy with cyclosporine, mycophenolate mofetil & prednisone